Atara Biotherapeutics (ATRA) Liabilities and Shareholders Equity (2013 - 2026)

Atara Biotherapeutics has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $20.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 67.77% year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $107.3 million (down 75.11% YoY), and the FY2025 full-year result was $20.2 million, down 81.45% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $20.0 million, down from $20.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $436.1 million in Q2 2022, with the low at $20.0 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $187.3 million across 5 years, with a median of $165.3 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slipped 4.53% — and 2025, when it sank 81.45%.
• Atara Biotherapeutics' Liabilities and Shareholders Equity stood at $376.4 million in 2022, then slumped by 56.03% to $165.5 million in 2023, then slumped by 34.08% to $109.1 million in 2024, then slumped by 81.45% to $20.2 million in 2025, then dropped by 1.18% to $20.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $20.0 million (Q1 2026), $20.2 million (Q4 2025), and $30.2 million (Q3 2025), per Business Quant data.